Author

Elisabetta Bugianesi

The NASH pandemic
The NASH pandemic

Elisabetta Bugianesi

NAFLD: From basic mechanisms to new therapies
NAFLD: From basic mechanisms to new therapies

Elisabetta Bugianesi

TOFACITINIB RELATED CANCER RISK: RESULTS FROM A SYSTEMATIC REVIEW WITH META-ANALYSIS
TOFACITINIB RELATED CANCER RISK: RESULTS FROM A SYSTEMATIC REVIEW WITH META-ANALYSIS

Elisabetta Bugianesi  et al.

CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWEL DISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME
CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWEL DISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME

Elisabetta Bugianesi  et al.

MULTIPLE SCLEROSIS PREVALENCE IN HIGHER IN CROHN’S DISEASE PATIENTS THAN IN GENERAL POPULATION, BUT DOES NOT INFLUENCE INFLAMMATORY BOWEL DISEASE OUTCOME
MULTIPLE SCLEROSIS PREVALENCE IN HIGHER IN CROHN’S DISEASE PATIENTS THAN IN GENERAL POPULATION, BUT DOES NOT INFLUENCE INFLAMMATORY BOWEL DISEASE OUTCOME

Elisabetta Bugianesi  et al.

PRO-TUMORIGENIC INFLAMMATORY RESPONSE INDUCED BY ONCOSTATIN M / ONCOSTATIN M RECEPTOR Β AXIS IN NASH-RELATED HCC
PRO-TUMORIGENIC INFLAMMATORY RESPONSE INDUCED BY ONCOSTATIN M / ONCOSTATIN M RECEPTOR Β AXIS IN NASH-RELATED HCC

Elisabetta Bugianesi  et al.

Item 1 - 6 / 6
1